Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity
- PMID: 21150709
- DOI: 10.1097/CJI.0b013e3181f7dbe8
Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity
Abstract
Direct vaccination with messenger RNA (mRNA) molecules encoding tumor-associated antigens is a novel and promising approach in cancer immunotherapy. The main advantage of using mRNA for vaccination is that the same molecule not only provides an antigen source for adaptive immunity, but can simultaneously bind to pattern recognition receptors, thus stimulating innate immunity. However, achieving both features remains challenging, as the complexation of mRNA required for immune-stimulating activity may inhibit its translatability. In this study, we present a new and more effective vaccine design: a two-component mRNA-based tumor vaccine that supports both: antigen expression and immune stimulation, mediated by Toll like receptor 7 (TLR7). The two-component mRNA vaccines, containing free and protamine-complexed mRNA, induce balanced adaptive immune responses providing humoral as well as T cell mediated immunity. This balanced immune response is based on the induction of antigen-specific CD4(+) T helper cells and cytotoxic CD8(+) T cells. Once activated, these CD4(+) and CD8(+) T cells secrete a wide set of cytokines, which drive a TH1 response. Immunization with the two-component vaccines induces sustained memory responses, mediated by antigen-specific memory T cells. Moreover, treatment of mice with the two-component mRNA vaccine mediates a strong antitumor response against OVA-expressing tumor cells, not only in a prophylactic but also in a therapeutic setting. In conclusion, two-component mRNA vaccines with self-adjuvanting activity induce balanced adaptive immune responses and mediate sustained antitumor activity.
Trial registration: ClinicalTrials.gov NCT00831467 NCT00906243 NCT00923312.
Comment in
-
mRNA: delivering an antitumor message?Immunotherapy. 2011 May;3(5):605-7. doi: 10.2217/imt.11.28. Immunotherapy. 2011. PMID: 21554090
Similar articles
-
Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect.J Gene Med. 2012 Jun;14(6):428-39. doi: 10.1002/jgm.2605. J Gene Med. 2012. PMID: 22262664
-
The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.Int J Oncol. 2006 Apr;28(4):947-53. Int J Oncol. 2006. PMID: 16525645
-
Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.J Leukoc Biol. 2007 Oct;82(4):829-38. doi: 10.1189/jlb.0407249. Epub 2007 Jul 11. J Leukoc Biol. 2007. PMID: 17626150
-
Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.Haematologica. 2002 Sep;87(9):989-1001. Haematologica. 2002. PMID: 12217812 Review.
-
Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development.J Cell Biochem. 2011 Aug;112(8):1969-77. doi: 10.1002/jcb.23126. J Cell Biochem. 2011. PMID: 21465529 Review.
Cited by
-
Advancing personalized medicine in brain cancer: exploring the role of mRNA vaccines.J Transl Med. 2023 Nov 18;21(1):830. doi: 10.1186/s12967-023-04724-0. J Transl Med. 2023. PMID: 37978542 Free PMC article. Review.
-
Advances in Engineering Circular RNA Vaccines.Pathogens. 2024 Aug 15;13(8):692. doi: 10.3390/pathogens13080692. Pathogens. 2024. PMID: 39204292 Free PMC article. Review.
-
RNA with chemotherapeutic base analogues as a dual-functional anti-cancer drug.Oncoimmunology. 2022 Nov 18;11(1):2147665. doi: 10.1080/2162402X.2022.2147665. eCollection 2022. Oncoimmunology. 2022. PMID: 36419823 Free PMC article.
-
CD8 T-cell priming upon mRNA vaccination is restricted to bone-marrow-derived antigen-presenting cells and may involve antigen transfer from myocytes.Immunology. 2015 Oct;146(2):312-26. doi: 10.1111/imm.12505. Epub 2015 Aug 28. Immunology. 2015. PMID: 26173587 Free PMC article.
-
mRNA vaccines in tumor targeted therapy: mechanism, clinical application, and development trends.Biomark Res. 2024 Aug 31;12(1):93. doi: 10.1186/s40364-024-00644-3. Biomark Res. 2024. PMID: 39217377 Free PMC article. Review.
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials